Zacks: Relmada Therapeutics Inc (RLMDD) Receives Average Rating of “Buy” from Brokerages
Relmada Therapeutics Inc (NASDAQ:RLMDD) has received an average broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Relmada Therapeutics’ rating score has improved by 33.3% in the last three months as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1 year consensus target price of $8.00 for the company and are predicting that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also given Relmada Therapeutics an industry rank of 99 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Relmada Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/zacks-relmada-therapeutics-inc-rlmdd-receives-average-rating-of-buy-from-brokerages.html
Relmada Therapeutics (NASDAQ:RLMDD) remained flat at $4.72 during mid-day trading on Wednesday. The stock has a 50 day moving average price of $3.11 and a 200 day moving average price of $5.64. The company has a market capitalization of $56.64 million and a P/E ratio of 9.22. Relmada Therapeutics has a one year low of $2.00 and a one year high of $19.90.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Relmada Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.